Q2 2024 EPS Estimates for Zoetis Inc. (NYSE:ZTS) Reduced by William Blair

Zoetis Inc. (NYSE:ZTS) – Research analysts at William Blair dropped their Q2 2024 earnings estimates for Zoetis in a research report issued on Thursday, May 2nd. William Blair analyst B. Vazquez now expects that the company will post earnings per share of $1.46 for the quarter, down from their previous estimate of $1.49. The consensus estimate for Zoetis’ current full-year earnings is $5.77 per share. William Blair also issued estimates for Zoetis’ Q3 2024 earnings at $1.48 EPS, Q4 2024 earnings at $1.43 EPS, FY2024 earnings at $5.76 EPS, Q1 2025 earnings at $1.53 EPS, Q2 2025 earnings at $1.64 EPS, Q3 2025 earnings at $1.66 EPS, Q4 2025 earnings at $1.61 EPS and FY2025 earnings at $6.43 EPS.

Several other research analysts have also issued reports on the stock. The Goldman Sachs Group increased their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Piper Sandler reissued an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Stifel Nicolaus decreased their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, Barclays reduced their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $216.13.

Zoetis Price Performance

NYSE:ZTS opened at $167.07 on Monday. The company has a market capitalization of $76.41 billion, a price-to-earnings ratio of 32.19, a PEG ratio of 2.61 and a beta of 0.86. The company has a 50-day moving average of $168.88 and a 200-day moving average of $178.93. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.74% and a net margin of 27.38%. Zoetis’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business earned $1.31 earnings per share.

Institutional Trading of Zoetis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Blue Bell Private Wealth Management LLC grew its stake in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares during the period. Webster Bank N. A. raised its holdings in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares during the period. Independence Bank of Kentucky lifted its stake in Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares in the last quarter. Private Wealth Management Group LLC acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $33,000. Finally, Ramirez Asset Management Inc. bought a new stake in shares of Zoetis during the third quarter worth $35,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the sale, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 2,209 shares of company stock valued at $371,293 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.03%. Zoetis’s dividend payout ratio (DPR) is currently 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.